In November 2024, the FDA approved VALEDA Photobiomodulation for patients with dry age-related macular degeneration (AMD).
This potentially groundbreaking treatment for patients with dry AMD uses 3 non-coherent wavelengths of light in the near infrared spectrum to stimulate the macula. It is believed that light in this spectrum activates cytochrome C oxidase in the macular mitochondria causing them to enhance ATP and energy production–essentially rejuvenating them.
The pivotal LIGHTSITE III (https://journals.lww.com/retinajournal/fulltext/2024/03000/lightsite_iii__13_month_efficacy_and_safety.14.aspx) study showed a remarkable improvement in vision and anatomical outcomes for patients treated with VALEDA. Please click on the link for more information:
We are proud to be one of the first sites in NY and the United States able to offer this breakthrough treatment to our patients.
We would be delighted to answer any questions you may have about VALEDA. Please call 212-439-9600 or email VALEDA@Maculacare.com
